---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-089564"
form_type: "8-K"
ticker: "TRAW"
cik: "0001130598"
company_name: "Traws Pharma, Inc."
filed_at: "2025-09-12T23:59:59+00:00"
generated_at: "2026-05-17T06:43:07.658107+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Traws Pharma acquires antiviral compound assets from Viriom for $2.35M cash

## Summary
- Acquired IP and assets for pyrrolidine antiviral compound from Viriom for $2,350,000 cash paid on September 9, 2025.
- Nikolay Savchuk, Traws COO, is Executive Chairman of Viriom; Dr. Robert Redfield, Traws CMO, on Viriom board; related-party transaction approved by audit committee.
- Assets include patents, license agreements, regulatory filings, and materials exclusively related to the compound and program.

## SEC filing metadata
- accession: 0001104659-25-089564
- form_type: 8-K
- ticker: TRAW
- cik: 0001130598
- company_name: Traws Pharma, Inc.
- filed_at: 2025-09-12T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 2.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1130598/000110465925089564/0001104659-25-089564-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1130598/000110465925089564/tm2526017d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-089564
- JSON: https://secwatch.observer/filing/0001104659-25-089564.json
- Plain text: https://secwatch.observer/filing/0001104659-25-089564.txt

## Source-grounded claims
- claim_id: 41d7deb65950edc38cb04a85f641e442a72ee147
  claim: Traws Pharma, Inc. completed an acquisition involving Virom, Inc. for $2,350,000 in cash (closed 2025-09-09).
  evidence_excerpt: On September 9, 2025, Traws Pharma, Inc. (the “Company”) and Virom, Inc. (“Viriom”) entered into an Asset Purchase Agreement (the “Purchase Agreement”), pursuant to which the Company purchased certain assets (the “Purchased Assets”) from Viriom in exchange for $2,350,000 in cash (the “Purchase Price”), which was paid in full to Virom on September 9, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1130598/000110465925089564/0001104659-25-089564-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.